Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | PGD | P52209 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967208 | 1.00 | SLC22A6 (0.48) | SLC22A6SMN1; SMN2CETPPGDGABRR1 | |
| SCHEMBL321641 | 1.00 | SLC22A6 (0.48) | SLC22A6SMN1; SMN2CETPPGDGABRR1 | |
| SCHEMBL12965457 | 0.81 | ALDH1A1 (0.43) | CETPPGDTDP1PKMMAPT | |
| SCHEMBL10335801 | 0.80 | CETP (0.46) | SLC22A6CETPLMNAPKMHTT | |
| SCHEMBL10335654 | 0.80 | CETP (0.46) | SLC22A6CETPLMNAPKMHTT | |
| SCHEMBL10335818 | 0.80 | CETP (0.46) | SLC22A6CETPLMNAPKMHTT | |
| SCHEMBL16877270 | 0.79 | SLC22A6 (0.43) | SLC22A6SMN1; SMN2PGDGABRR1LMNA | |
| SCHEMBL28191246 | 0.77 | SLC22A6 (0.42) | SLC22A6SMN1; SMN2PGDGABRR1LMNA | |
| SCHEMBL23326065 | 0.76 | CETP (0.42) | CETPPKMHTT | |
| SCHEMBL15415836 | 0.76 | CETP (0.48) | CETPLMNATDP1PKMHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192821-A1 | ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2023-06-14 | — | — | EP | claimed |
| EP-1054974-B1 | METHOD FOR PRODUCING TRIFLUORO-3(R)-HYDROXYBUTYRIC ACID DERIVATIVES | LONZA AG (CH) | 2007-03-28 | — | — | EP | claimed |
| US-6893861-B1 | Method for producing trifluoro-3(r)-hydroxybutyric acid derivatives | LONZA AG (CH) | 2005-05-17 | — | — | US | claimed |
| EP-0736606-B1 | Process for the enzymatic preparation of intermediates for the synthesis of befloxatone | SANOFI SYNTHELABO (FR) | 2002-01-02 | — | — | EP | claimed |
| US-5716841-A | Process for the resolution of ethyl 4,4,4-trifluoro-3(R)-hydroxybutanoate using lipase from candida | SYNTHELABO (FR) | 1998-02-10 | — | — | US | claimed |
| EP-0736606-A1 | Process for the enzymatic preparation of intermediates for the synthesis of befloxatone | SYNTHELABO (FR) | 1996-10-09 | — | — | EP | claimed |
| JP-3151348-A | — | — | None | — | — | JP | disclosed |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-3962602-B1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-20230381132-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| EP-4237402-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| EP-0736606-A1 | Process for the enzymatic preparation of intermediates for the synthesis of befloxatone | SYNTHELABO (FR) | 1996-10-09 | — | — | EP | disclosed |
| EP-0427396-B1 | Process for producing optically active fluorine-containing 3-hydroxybutyric acid esters | SHOWA SHELL SEKIYU (JP) | 1994-09-14 | — | — | EP | disclosed |
| US-5196543-A | Antidepressants, tranquilizers | DELALANDE S.A. (FR) | 1993-03-23 | — | — | US | disclosed |
| US-5118836-A | OPTICALLY ACTIVE FLUORINE-CONTAINING 3-HYDROXYBUTYRIC ACID ESTERS AND PROCESS FOR PRODUCING THE SAME | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1992-06-02 | — | — | US | disclosed |
| US-5036091-A | Psychotropic drugs | DELALANDE S.A. (FR) | 1991-07-30 | — | — | US | disclosed |
| JP-H03151348-A | OPTICALLY ACTIVE FLUORINE-CONTAINING 3-HYDROXYBUTYRIC ESTERS AND PRODUCTION THEREOF | SHOWA SHELL SEKIYU KK | 1991-06-27 | — | — | JP | disclosed |
| EP-0427396-A2 | Process for producing optically active fluorine-containing 3-hydroxybutyric acid esters | Showa Shell Sekiyu Kabushiki Kaisha (JP) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381132-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, RCOR3 | SLC22A6 4083/4885SMN1; SMN2 2886/4885CETP 1818/4885 |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | IL1R1, IL1B, IL1A | SLC22A6 1808/4885SMN1; SMN2 3731/4885CETP 3206/4885 |
| US-20230399289-A1 | ITACONIC ACID DERIVATIVES | IL1R1, LRBA, HCAR1 | SLC22A6 1533/4885SMN1; SMN2 3304/4885CETP 3531/4885 |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | PTGS1, PTGER1, PTGES2 | SLC22A6 3483/4885SMN1; SMN2 2007/4885CETP 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.